跳至主要内容
临床试验/ISRCTN69220108
ISRCTN69220108已完成未知

The use of a prognostic tool (EndoPredict®) to inform adjuvant chemotherapy decision in low to medium risk oestrogen receptor positive, Her­-2 negative early breast cancer: feasibility, acceptability and economic impact in multicentre UK NHS practice

Brighton & Sussex University Hospitals NHS Trust0 个研究点目标入组 149 人开始时间: 2015年8月19日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
149

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Women over 18 years of age with first presentation of early Oestrogen Receptor +ve and HER­2
  • 2. Negative breast cancer with all known disease surgically removed
  • 3. Women who have an unclear decision regarding chemotherapy based on standard prognostic criteria
  • 4. Performance status and general health sufficient in the judgement of the treating oncologist to manage adjuvant chemotherapy
  • 5. Ability to understand verbal and written English

排除标准

  • 1. Patients unwilling to accept adjuvant chemotherapy
  • 2. Patients unable to give full informed consent

研究者

相似试验